Amyl Therapeutics Closes €18.3M Series A Financing To Develop Novel Therapies For Amyloidosis

by prnewswire.com posted 2weeks ago 3 views
LIEGE, Belgium, June 3, 2021 /PRNewswire/ -- Amyl Therapeutics ('Amyl'), a preclinical stage biotechnology company developing its amyloid fibrils specific technology platform named ClariTY for the treatment of all forms of Amyloidosis, today announced that it has successfully closed a €18....

In this article

No tags related to this article.